Together, our findings highlight the potential of neutrophil-specific STAT3 inhibition as a promising strategy for harnessing myeloid cells in cancer immunotherapy and provide new insights into reprogramming the innate immune compartment to strengthen anti-tumor immunity. Here, STAT3 is linked to neoplasm.